Abstract: The present invention encompasses a cancer vaccine therapy targeting Aspartyl-[Asparaginyl]-,8-hydroxylase (HAAH). The present invention contemplate bacteriophage expressing HAAH peptide fragments and methods for using said bacteriophage in methods of treating cancer.

Abstract: The present invention is directed to compositions and method for providing radio-imaging and radiotherapy for cancer. In particular, methods for making and using radio-labeled anti-HAAH antibodies for tumor imaging and immunotherapy are provided.

Abstract: The present invention encompasses a cancer vaccine therapy targeting Aspartyl-[Asparaginyl]-?-hydroxylase (HAAH). The present invention contemplate bacteriophage expressing HAAH peptide fragments and methods for using said bacteriophage in methods of treating cancer.

Abstract: The present invention encompasses a cancer vaccine therapy targeting Aspartyl-[Asparaginyl]-beta.-hydroxylase (HAAH). The present invention contemplates bacteriophage expressing HAAH peptide fragments and methods for using said bacteriophage in methods of treating cancer.

Abstract: The present invention is directed to compositions and method for providing radio-imaging and radiotherapy for cancer. In particular, methods for making and using radio-labeled anti-HAAH antibodies for tumor imaging and immunotherapy are provided.

Abstract: The present invention provides methods and compositions preventing and treating radical prostatectomy-induced erectile dysfuntion. One embodiment of the present invention is directed to a method of preventing and treating radical prostatectomy-induced erectile dysfuntion by administering to a patient in need at least one thiosemicarbazone compound.

Abstract: The present invention provides methods and compositions for treating chemotherapy induced peripheral neuropathy. One embodiment of the present invention is directed to a method of treating chemotherapy induced peripheral neuropathy by administering to a patient in need at least one thiosemicarbazone compound.

Abstract: The present invention encompasses a cancer vaccine therapy targeting Aspartyl-[Asparaginyl]-?-hydroxylase (HAAH). The present invention contemplate bacteriophage expressing HAAH peptide fragments and methods for using said bacteriophage in methods of treating cancer.

Abstract: The present invention provides methods and compositions for treating chemotherapy-induced cognitive impairment. One embodiment of the present invention is directed to a method of treating chemotherapy-induced cognitive impairment by administering to a patient in need at least one thiosemicarbazone compound.

Abstract: The present invention encompasses a cancer vaccine therapy targeting Aspartyl-[Asparaginyl]-?-hydroxylase (HAAH). The present invention contemplate bacteriophage expressing HAAH peptide fragments and methods for using said bacteriophage in methods of treating cancer.

Abstract: The present invention relates to drug screening methods and methods of preventing neural tissue damage caused by ?-synuclein aggregation. These methods are especially useful in the design and development of inhibitors of Lewy body diseases and other synucleinopathies, and further useful in the treatment of such neurodegenerative diseases, particularly Parkinson's Disease.

Abstract: The invention is related to the treatment of prion-related diseases such as the transmissible spongiform encephalopathies (TSEs) in mammals by administering chaotropic agents to or inducing a hyperthermia state in the affected mammals.

Abstract: The present invention relates to methods of treating ischemia-related conditions by administering to a patient in need of such methods certain thiosemicarbazone compounds. Preferred embodiments of the present invention relates to methods of treating specific ischemia-related conditions, including but not limited to Alzheimer's disease, Parkinson's disease, Coronary artery bypass graft surgery, Global cerebral ischemia due to cardiac arrest, focal cerebral infarction, cerebral hemorrhage, hemorrhage infarction, hypertensive hemorrhage. hemorrhage due to rupture of intracranial vascular abnormalities, subarachnoid hemorrhage due to rupture of intracranial arterial aneurysms, hypertensive encephalopathy, carotid stenosis or occlusion leading to cerebral ischemia, cardiogenic thromboembolism, spinal stroke and spinal cord injury, diseases of cerebral blood vessels: e.g., atherosclerosis, vasculitis, Macular degeneration, myocardial infarction, cardiac ischemia and superaventicular tachyarrhytmia.

Abstract: The invention discloses methods for leukemia diagnosis and determining the effectiveness of certain therapies. The methods of the present invention also encompass a way to predict a subject's responsiveness to therapeutic interventions for leukemia, as well as to monitor relapse during treatment due to therapeutic resistance. Further, the methods disclosed can be used to screen for effective therapeutic agents or regimens, either generally or in a specific patient. The invention also provides a unique diagnostic tool for leukemia.

Abstract: The present invention provides methods of determining aggregation of &agr;-synuclein, which are a hallmark of Lewy body diseases such as Parkinson's disease. Also disclosed are inhibitors of the aggregation, including magnesium and &agr;-synuclein binding peptides. The inhibitors are useful in the treatment of Lewy body diseases.

Abstract: Olfactory neuron cultures and methods of making and using the same are disclosed. The olfactory neuron cultures may be used to study oxidative stress-related disorders and diseases such as Alzheimer's disease. The olfactory neuron cultures may be used to screen candidate compounds for those which reduce, inhibit or prevent oxidative stress or damage. The compounds which reduce, inhibit or prevent oxidative stress or damage may be used to treat Alzheimer's disease and other oxidative stress-related disorders and diseases.

Abstract: Olfactory neuron cultures and methods of making and using the same are disclosed. The olfactory neuron cultures may be used to study oxidative stress-related disorders and diseases such as Alzheimer's disease. The olfactory neuron cultures may be used to screen candidate compounds for those which reduce, inhibit or prevent oxidative stress or damage. The compounds which reduce, inhibit or prevent oxidative stress or damage may be used to treat Alzheimer's disease and other oxidative stress-related disorders and diseases.

Abstract: Compositions are administered to block IgE binding to receptors and ultimately displace native IgE from mast cells and related cell types, to prevent the activation of these cells during an allergic response. The compositions consist of a pharmaceutically acceptable carrier for systemic or local administration and an amount of compound binding specifically to the Fc&egr;RI IgE binding sites, and more preferably, Fc&egr;RI and Fc&egr;RII IgE binding sites, to prevent activation and degranulation of mast cells in response to exposure to allergens. The compounds can consist of IgE molecules and fragments and modifications thereof, such as IgE fragments, humanized or single chain IgE antibodies or fragments thereof, IgE with a modified Fab, non-crosslinkable IgE, or peptidomimetics which bind to the same site on the receptor as the IgE, jointly referred to herein as “IgE fragments” unless otherwise stated.

Abstract: It has been discovered that one can predict the likelihood a child will outgrow an allergy, especially a food allergy, by screening for IgE antibodies immunoreactivities with linear versus conformational epitopes. The child is first screened using standard techniques to determine what antigens the child is allergic to. The immunoglobulins in the sample from the patient are then characterized either using the natural purified antigen, recombinant antigen, reduced and alkylated antigen, proteolytic fragments of the antigen or synthetic peptides of between four and 40 amino acids in length, preferably six to ten amino acids, which can be immobilized for rapid and accurate screening. The antibodies from the patient, typically present in a serum or plasma sample, are reacted with the protein or peptides to determine which peptides are bound by the antibodies. These antibodies are then characterized to determine if the epitopes they bind are linear or conformational.